Sanmirna
Amsterdam, US · 1 known investors
Find your way into Sanmirna
Sanmirna Therapeutics develops microRNA-targeted therapeutics for cancer treatment, with its lead candidate Miristen™ currently in Phase I clinical trials for acute myeloid leukemia. The company leverages microRNA discovery to create novel oncology treatments.
Investors · 1
NLClisted by NLCAmsterdam
How we know: NLC's portfolio page · Not right? Tell us
In the news
Frequently asked questions
- What does Sanmirna do?
- Sanmirna Therapeutics develops microRNA-targeted therapeutics for cancer treatment, with its lead candidate Miristen™ currently in Phase I clinical trials for acute myeloid leukemia. The company leverages microRNA discovery to create novel oncology treatments.
- Who are Sanmirna's investors?
- Sanmirna's investors include NLC.
- Where is Sanmirna headquartered?
- Sanmirna is headquartered in Amsterdam, US.